Medical Marijuana, Inc. Subsidiary Kannaway® Celebrates New Milestone; Achieves Best Revenue Month in Company History for Japan Division in December 2021
SAN DIEGO, CA, Jan. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived more...
What Makes DLH Holdings Corp. (DLHC) a Good Fit for “Trend Investing”
Most of us have heard the dictum “the trend is your friend.” And this is undeniably the key to success when it comes to short-term investing or trading. But it isn’t easy to ensure the more...
Aileron Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., more...
Item 9 Labs Corp. Enhances Board of Directors with Two Independent Appointments
Item 9 Labs Corp. Enhances Board of Directors with Two Independent Appointments Names Eric C. Kutscher and Lawrence X. Taylor to Board of Directors; Adds a Combined 55-Plus Years of Experience Across Patient-Centered Healthcare, Leadership, more...
Is DLH (DLHC) Stock a Solid Choice Right Now?
One stock that might be an intriguing choice for investors right now is DLH Holdings Corp. DLHC . This is because this security in the Staffing Firms space is seeing solid earnings estimate revision activity, more...
Evoke Pharma to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference
SOLANA BEACH, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (G.I.) diseases, today announced that the Company will participate in the more...
Conformis, Inc. to Provide Business Update and Initial Expectations for 2022 on January 6, 2022
BILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thursday, January 6, 2022, more...
Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint
‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒ BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd . (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 more...
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Topline ORCA-2 Results Expected in Q2 2022 SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and more...
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference
FLORHAM PARK, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced more...